DGAP-Adhoc: 4SC AG issues second tranche of convertible notes with a nominal amount of EUR 500,000 to Yorkville

4SC AG  / Key word(s): Corporate Action

03.09.2014 15:07

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Publication of an ad hoc release pursuant to Section 15 of the German
Securities Trading Act (Wertpapierhandelsgesetz, WpHG)

4SC AG issues second tranche of convertible notes with a nominal amount of
EUR 500,000 to Yorkville

Planegg-Martinsried, 3 September 2014 - 4SC AG (Frankfurt, Prime Standard:
VSC) today announced that it successfully completed the issuance of
convertible notes with a nominal amount of EUR 500,000.00. 4SC will use the
proceeds for the further preparation of a planned clinical Phase II study
with its cancer compound resminostat in the liver cancer indication.

These convertible notes constitute the second tranche of a total issuance
of up to EUR 15 million guaranteed by an agreement between YA Global Master
SPV Ltd. ("Yorkville") and the Company, as announced in an ad hoc release
dated 12 February 2014. Prior to this, a first tranche of convertible notes
issued in March 2014 of nominally EUR 500,000.00 was completely converted
into shares. Following the successful conversion of previously issued
tranches, 4SC's Management will decide independently on a case-by-case
basis whether additional tranches will be issued.

Excluding the pre-emptive rights of existing shareholders, the convertible
notes will be issued exclusively to Yorkville at a subscription price
corresponding to 95% of the nominal amount. The notes carry no interest,
have a term of nine month and may be converted into shares of 4SC by the
holder of the notes at any time. The conversion price equals the volume
weighted average trading price of 4SC shares during a five-day period prior
to the time of conversion, less a 5% discount, but it cannot be lower than
EUR 1.00.

Ad hoc ends

Additional information of the issuer of this release

About 4SC 

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount
of 65 employees (55 FTEs) at 30 June 2014. 4SC AG has been listed on the
Prime Standard of the Frankfurt Stock Exchange since December 2005.

Cautionary statement regarding forward-looking statements 

This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.

For more information please visit www.4sc.com or contact:

4SC AG 
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

MC Services 
Katja Arnold, Michelle Kremer
katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

The Trout Group 
Chad Rubin 
crubin(at)troutgroup.com, Tel.: +1-646-378-2947


03.09.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      4SC AG
              Am Klopferspitz 19a
              82152 Martinsried
              Germany
Phone:        +49 (0)89 7007 63-0
Fax:          +49 (0)89 7007 63-29
E-mail:       public@4sc.com
Internet:     www.4sc.de
ISIN:         DE0005753818
WKN:          575381
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------